Collaboration Arrangements - Additional Information (Detail) - Merck KGaA - USD ($) $ in Millions |
12 Months Ended | 47 Months Ended | |||
---|---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Dec. 31, 2012 |
Dec. 31, 2015 |
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Upfront and milestone payments received to date | $ 110.0 | $ 110.0 | |||
Collaboration payments achieved and received | $ 42.5 | $ 67.5 | |||
Revenue recognized by the Company | 76.9 | $ 14.7 | 12.5 | ||
Company received a reimbursement for eligible worldwide development expenses | $ 11.6 | $ 21.9 | $ 16.5 | ||
Collaborative Arrangement Product Agreement | Evofosfamide | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Merck KGaA's percentage share of worldwide development expenses | 70.00% |
X | ||||||||||
- Definition Collaboration payments achieved and received. No definition available.
|
X | ||||||||||
- Definition Merck KGaA's percentage share of worldwide development expenses. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|